Desipramine pharmacokinetics

Rudorfer MV, Lan EA, Chang WH, et al (1984) Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 17 433-440... 

Alderman, J., Preskorn, S.H., Greenblatt, D.J., Harrison, W., Penen-berg, D., Allison, J., and Chung, M. (1997) Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. / Clin Psychopharmacol 17 284-291. 

Furman KD, Grimm DR, Mueller T, Holley-Shanks RR, Bertz RJ, Williams LA, Spear BB, Katz DA. Impact of CYP2D6 intermediate me-tabolizer alleles on single-dose desipramine pharmacokinetics, Pharmacogenetics 2004 14(5) 279-284. 

Atomoxetine did not aiter desipramine pharmacokinetics and wouid therefore not be expected to affect other substrates of CYP2D6. Atomoxetine did not aiter midazolam pharmacokinetics and wouid therefore not be expected to affect other substrates of CYP3A4. Antacids and omeprazole do not alter atomoxetine bioavaiiabiiity. 

Atomoxetine 40 or 60 mg twice daily for 13 days was given to 21 subjects who were extensive metabolisers of CYP2D6 (most common phenotype), with a single 50-mg dose of desipramine on day 4. Atomoxetine had no effect on desipramine pharmacokinetics. ... 

In one study, healthy subjects were given desipramine 25 mg three times daily for 3 days then 50 mg three times daily for 10 days. For the last 5 days they were also given levodopa/carbidopa 100/25 mg three times daily and either a placebo or tolcapone 200 mg three times daily. The addition of tolcapone to combined treatment with levodopa/carbidopa and desipramine did not lead to any changes in haemodynamics or catecholamine levels, nor to any changes in desipramine pharmacokinetics. ... 

Brookes AJ, Lehvaslaiho H, Siegfried M, et al (2000) HGBASE a database of SNPs and other variations in and around human genes. Nucleic Acids Res 28 356-360 Brosen K, Naranjo CA (2001) Review of pharmacokinetic andpharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 11 275-283 Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44 349-355... 

Chuang DM, Gao X-M, Paul SM N-methyl-D-aspartate exposure blocks glutamate toxicity in cultured cerebellar granule cells. Mol Pharmacol 42 210-216, 1992 Chugh Y, Saha N, Sankaranarayanan A, et al Enhancement of memory retrieval and attenuation of scopolamine-induced amnesia following administration of S-HTj antagonist ICS 205-930. Pharmacol Toxicol 69 105-106, 1991 Ciraulo DA, Jaffe JH Tricyclic antidepressants in the treatment of depression associated with alcoholism. Clin Psychopharmacol 1 146, 1981 Ciraulo DA, Barnhill JG, Jaffe JH Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Pharmacol Ther 43 539-548, 1988... 

Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994 14 90-98. 

Kurtz DL, Bergstrom RF, Goldberg MJ, et al. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997 62 145-156. 

Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol 2002 42(ll) 1211-8. 

Psychiatric patients often take multiple psychotropic medications and have medical illnesses that require additional pharmacother-apeutic treatments. Psychiatric practitioners must recognize that administration of multiple medications can alter pharmacokinetic profiles of compounds that are biotransformed by the CYP enzymes. For example, the addition of the popular selective serotonin reuptake inhibitor (SSRI) fluoxetine to a treatment regimen for depression that includes the TCA desipramine has been reported to produce toxic levels of the TCA because of competi-... 

Lin et al. (submitted) examined the pharmacokinetics of imi-pramine and desipramine in 28 African Americans, 33 Asians, 28 Caucasians, and 30 Mexican Americans. The only significant differences in kinetic parameters were noted in the black cohort. African Americans displayed larger areas under the curve for and had higher maximum concentrations of desipramine. This study is concordant with that by Gaviria et al. (1986) in that no significant differences between Caucasian and Mexican American subjects were demonstrated. The increased area under the curve and maximum concentration in the African American group coincide with the slower metabolism seen with populations genetically similar to African blacks and with other reports of slow metabolism in African Americans (Strickland et al. 1991). 

Pi et al. (1986) compared the pharmacokinetics of 50 mg desipramine in 20 Asian volunteers and 75 mg desipramine in 20 Caucasian volunteers of both sexes. Asians were found to achieve peak plasma concentrations in significantly less time (4.0 hours vs. 6.9 hours). No other pharmacokinetic parameters were found... 

Essential Psychopharmacology 2 233-262,1998 Pi EH, Simpson GM Medication-induced movement disorders, in Kaplan and Sadock s Comprehensive Textbook of Psychiatry, 7th Edition. Edited by Sadock BJ, Sadock VA. Philadelphia, PA, Lippincott Williams Wilkins, 2000, pp 2265-2271 Pi EH, Jain A, Simpson GM Review and survey of different prescribing practices in Asia, in Biological Psychiatry. Edited by Shagass C, Jo-siassen RC, Bridger WH, et al. New York, Elsevier, 1985, pp 1536-1538 Pi EH, Simpson GM, Cooper TB Pharmacokinetics of desipramine in Caucasian and Asian volunteers. Am J Psychiatry 143 1174-1176,1986 Pi EH, Tran-Johnson TK, Walker NR, et al Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacol Bull 25 483M87,1989... 

Coadministration of cimetidine reduced citalopram oral clearance by 29%, whereas the addition of fluvoxamine caused a significant increase in plasma concentrations of citalopram. At this time, esci-talopram is considered unbkely to be involved in cbnically important pharmacokinetic interactions, althongh coadministration of escitalo-pram and desipramine resnlted in a donbling of the area nnder the cnrve for desipramine. ... 

Terlinden, R. Borbe, H.O. Determination of amitriptylinoxide and its major metabolites amitriptyline and nortriptyline in plasma by high-performance liquid chromatography. J.Chromatogr., 1986, 382, 372-376 [plasma column temp 45 extracted amitriptylinoxide desipramine (IS) LOQ 10 ng/mL pharmacokinetics dog]... 

Rutledge, D.R. Abadi, A.H. Lopez, L.M. Beaudreau, C.A. High-performance liquid chromatographic determination of diltiazem and two of its metabolites in plasma using a short alkyl chain silanol deactivated column. J.Chromatogr., 1993, 615, 111-116 [plasma extracted metabolites imipramine IS LOD 4 n mL pharmacokinetics interfering theophylline simultaneous desipramine, propranolol, verapamil non-interfering aspirin, atenolol, caffeine, ibuprofen, lidocaine, metoprolol, nifedipine]... 

---